The Why, what, and How of the New FACT standards for immune effector cells

Novel cellular therapies outside of traditional hematopoietic stem cell transplantation or hematopoietic progenitor cell (HPC) therapy are currently under evaluation in clinical trials across the United States and around the world. Several cellular products, e.g., CD19-directed Chimeric Antigen Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Maus, Marcela V., Nikiforow, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394615/
https://www.ncbi.nlm.nih.gov/pubmed/28428885
http://dx.doi.org/10.1186/s40425-017-0239-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394615/
https://www.ncbi.nlm.nih.gov/pubmed/28428885
http://dx.doi.org/10.1186/s40425-017-0239-0

Ejemplares similares